Accueil/Actions/OMER

OMER

USD

Omeros Corporation Common Stock

$6.730-0.330 (-4.674%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$7.060

Haut

$7.240

Bas

$6.710

Volume

1.29M

Fondamentaux de l'Entreprise

Capitalisation Boursière

458.0M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

3.30M

Bourse

NGM

Devise

USD

Intervalle sur 52 Semaines

Bas $2.95Actuel $6.730Haut $13.6

Actualités Connexes

15 oct. 2025 · 12:34

Reuters

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disorders, they said on Wednesday.

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

15 oct. 2025 · 12:30

GlobeNewswire

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term